Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in North America and Europe with a median age of onset of 72. Due to the advanced age of most patients with CLL, many are unable to tolerate ...

Chronic lymphocytic leukemia (CLL) is a common leukemia, with a heterogeneous clinical course. When treatment is required, patients usually receive an alkylating agent, such as chlorambucil, or a nucleoside analogue, ...

The clinical course of patients with Chronic Lymphocytic Leukemia (CLL) is highly variable, and identifying genetic abnormalities that lead to aggressive disease is of prognostic and therapeutic importance. Telomere ...